About

LaMont J. Barlow, MD, is a urologist at NYU Langone Ambulatory Care Rego Park, dedicated to providing expert, compassionate care that enhances patients’ quality of life. He specializes in urologic oncology, treating various cancers of the urinary tract, including prostate, bladder, kidney, and testicular cancer. Additionally, he manages a wide range of urologic conditions. Dr. Barlow is committed to creating an affirming and inclusive environment, ensuring that every patient feels safe, respected, and heard, regardless of their background or identity. Throughout his career, he has been dedicated to mentorship and pipeline programming within NYU Langone and on a national level. He collaborates with fellow faculty members on initiatives to deliver the highest quality care to all patients, supporting inclusivity in the field of urology. His journey into medicine was driven by a fascination with the blend of advanced surgical techniques and the versatility of treatment modalities in urology. His education and training have equipped him with the skills and knowledge to provide top-tier care, and he is proud to be part of NYU Langone, working with an expert team to ensure comprehensive and coordinated care for his patients.

Research topics

• Genetics
• Biology
• Cancer research

Selected publications

• IP04-08 ONLINE MISINFORMATION ABOUT PROSTATE CANCER

  The Journal of Urology · 2025-04-08 · 1 citations

  article
  PublisherDOI

• Classification of Inaccurate Information About Prostate Cancer on Social Media in English and Spanish

  European Urology Oncology · 2025-10-30

  articleOpen access

  Inaccurate information about prostate cancer is widespread on online social networks in English and Spanish and spans a variety of topics from prevention and screening to treatment and survivorship. Clinicians should raise awareness that social media can be a source of misinformation about prostate cancer, preemptively address prevalent myths, and actively participate in public dissemination of evidence-based information.

  PublisherOA PDFDOI

• Patterns of Outpatient Urinalysis Testing and the Detection of Microscopic Hematuria

  Urology · 2025-07-15 · 1 citations

  article
  PublisherDOI

• Supplementary Video from The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer

  2025-11-24

  articleOpen access

  <p>Supplementary Video</p>

  PublisherDOI

• Downstream Impact of Social Media Use and Variable Quality of Online Information About Prostate Cancer

  European Urology Oncology · 2025-10-17 · 1 citations

  articleOpen access

  Social media can benefit prostate cancer care through education and empowerment, but also have the potential for exposure to misinformation, leading to adverse health and/or economic impacts for patients and damaging the patient-physician relationship. Clinicians should promote digital health literacy and provide recommended sources of reliable online content for additional information.

  PublisherOA PDFDOI

• Supplementary Tables from The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer

  2025-11-24

  articleOpen access

  <p>Supplementary Tables</p>

  PublisherDOI

• Combating online misinformation in clinical encounters

  British Journal of Urology · 2025-04-15 · 2 citations

  articleOpen access

  Stacy Loeb reports a research grant from Endo, and consulting with Astellas, Blue Earth, Endo, Doceree, and Savour Health, unrelated to the present manuscript. The remaining authors have no disclosures.

  PublisherOA PDFDOI

• Supplementary Figures from The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer

  2025-11-24

  articleOpen access

  <p>Supplementary Figures</p>

  PublisherDOI

• MP70-17 GLOBAL DISPARITIES IN CLINICAL TRIALS FOR BLADDER CANCER IMMUNE CHECKPOINT INHIBITORS AND ANTIBODY-DRUG CONJUGATES

  The Journal of Urology · 2024-04-15

  article

  You have accessJournal of UrologyDiversity, Equity & Inclusion: Health Equity & Outcomes III (MP70)1 May 2024MP70-17 GLOBAL DISPARITIES IN CLINICAL TRIALS FOR BLADDER CANCER IMMUNE CHECKPOINT INHIBITORS AND ANTIBODY-DRUG CONJUGATES Juan C. Angulo-Lozano, Andres Noyola-Perez, Gabriel Cojuc-Konigsberg, Hector A. Vaquera, Claudia Mendoza, Luisa F. Sanchez, Jimena Alcocer, Pavel S. Pichardo-Rojas, Parwiz Abrahimi, Lina Posada Calderon, LaMont J. Barlow, and Douglas Scherr Juan C. Angulo-LozanoJuan C. Angulo-Lozano , Andres Noyola-PerezAndres Noyola-Perez , Gabriel Cojuc-KonigsbergGabriel Cojuc-Konigsberg , Hector A. VaqueraHector A. Vaquera , Claudia MendozaClaudia Mendoza , Luisa F. SanchezLuisa F. Sanchez , Jimena AlcocerJimena Alcocer , Pavel S. Pichardo-RojasPavel S. Pichardo-Rojas , Parwiz AbrahimiParwiz Abrahimi , Lina Posada CalderonLina Posada Calderon , LaMont J. BarlowLaMont J. Barlow , and Douglas ScherrDouglas Scherr View All Author Informationhttps://doi.org/10.1097/01.JU.0001008796.84999.75.17AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Immune checkpoint inhibitors (ICI) and antibody-drug conjugates (ADC) have shown unprecedented results in clinical trials for bladder cancer (BCa). Nonetheless, the affordability and accessibility of these drug classes in low- and middle-income countries (LMICs) is still uncertain. This study aimed to explore the global distribution of ongoing clinical trials for ICIs and ADCs. METHODS: We searched the NCT and WHO International Clinical Trials Registry Portal registries for trials on ICIs and ADCs for bladder cancer. Two reviewers, in a duplicated and blinded fashion, manually searched and extracted data from each registry searching ICIs and ADCs for BCa. The countries were classified according to the 2023 World Bank Ranking into High-income countries (HICs) and LMICs. RESULTS: 197 clinical trials were included from 60 participating countries, revealing disparities across income classifications. 38 (63.3%) were HICs, while 22 (36.7%) were LMICs (Figure 1). Comparing participation, from the 1317 country mentions in the 197 trials, HICs appeared 4.15 times more frequently than LMICs (80.6% Vs. 19.4%). There were no participating LMICs from Phase I RCTs. People living in HIC had 23.07 times more clinical trials per capita compared to those from LMIC (9.02-7 vs 3.9-8). There was a statistically significant difference in the distribution of HICs and LMICs between the 5 ICIs (p<0.001) and 3 ADCs (p=0.042) (Table 1). CONCLUSIONS: Disparities exist in the participation of countries according to their income, with HICs comprising most participants. While 84.7% the global population live in LMICs, conducting clinical trials in these countries can provide valuable insights into the effectiveness and safety of interventions in populations with different genetic, environmental, and socio-economic backgrounds. This not only ensures the generalizability of trial results but also ensures that healthcare solutions adjust to meet the needs of diverse populations. Download PPT Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1135 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Juan C. Angulo-Lozano More articles by this author Andres Noyola-Perez More articles by this author Gabriel Cojuc-Konigsberg More articles by this author Hector A. Vaquera More articles by this author Claudia Mendoza More articles by this author Luisa F. Sanchez More articles by this author Jimena Alcocer More articles by this author Pavel S. Pichardo-Rojas More articles by this author Parwiz Abrahimi More articles by this author Lina Posada Calderon More articles by this author LaMont J. Barlow More articles by this author Douglas Scherr More articles by this author Expand All Advertisement PDF downloadLoading ...

  PublisherDOI

• Within and across population genomic predictions incorporating functional genomic annotations

  Socio-Environmental Systems Modeling · 2024-01-01

  articleOpen access
  Publisher

Frequent coauthors

• James M. McKiernan

  Columbia University

  65 shared

• Mitchell C. Benson

  39 shared

• Kevin P. Newhall

  Cleveland Clinic

  39 shared

• Bishoy M. Faltas

  Cornell University

  34 shared

• Kenneth Wha Eng

  32 shared

• David Golombos

  Rutgers, The State University of New Jersey

  32 shared

• Andrea Sboner

  Weill Cornell Medicine

  32 shared

• Olivier Elemento

  Weill Cornell Medicine

  32 shared